These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 7922706)

  • 1. Thymosin alpha-1 as adjunct for conventional therapy of malignant tumors: a review.
    Bepler G
    Cancer Invest; 1994; 12(5):491-6. PubMed ID: 7922706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thymosin alpha-1.
    Ancell CD; Phipps J; Young L
    Am J Health Syst Pharm; 2001 May; 58(10):879-85; quiz 886-8. PubMed ID: 11381492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: a randomized controlled study.
    You J; Zhuang L; Cheng HY; Yan SM; Yu L; Huang JH; Tang BZ; Huang ML; Ma YL; Chongsuvivatwong V; Sriplung H; Geater A; Qiao YW; Wu RX
    World J Gastroenterol; 2006 Nov; 12(41):6715-21. PubMed ID: 17075991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application.
    Garaci E; Pica F; Rasi G; Favalli C
    Int J Immunopharmacol; 2000 Dec; 22(12):1067-76. PubMed ID: 11137613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of the immunoregulatory properties of thymosin alpha 1 on interleukin-2 production and interleukin-2 receptor expression in normal human lymphocytes.
    Sztein MB; Serrate SA
    Int J Immunopharmacol; 1989; 11(7):789-800. PubMed ID: 2599716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of chronic hepatitis B: case selection and duration of therapy.
    Leung N
    J Gastroenterol Hepatol; 2002 Apr; 17(4):409-14. PubMed ID: 11982721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thymalfasin: an immune system enhancer for the treatment of liver disease.
    Sjogren MH
    J Gastroenterol Hepatol; 2004 Dec; 19(12):S69-72. PubMed ID: 15641207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II trial of thymosin fraction 5 and thymosin alpha one in HTLV-III seropositive subjects.
    Schulof RS; Simon GL; Sztein MB; Parenti DM; DiGioia RA; Courtless JW; Orenstein JM; Kessler CM; Kind PD; Schlesselman S
    J Biol Response Mod; 1986 Oct; 5(5):429-43. PubMed ID: 3490545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thymosin stimulates interleukin-6 production from rat spleen cells in vitro.
    Attia WY; Badamchian M; Goldstein AL; Spangelo BL
    Immunopharmacology; 1993; 26(2):171-9. PubMed ID: 8282541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial to evaluate the immunorestorative properties of synthetic thymosin-alpha 1 in patients with lung cancer.
    Schulof RS; Lloyd MJ; Cleary PA; Palaszynski SR; Mai DA; Cox JW; Alabaster O; Goldstein AL
    J Biol Response Mod; 1985 Apr; 4(2):147-58. PubMed ID: 3998766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of immunoreactive forms of thymosin alpha 1 in serum and supernatants by combining HPLC and RIA.
    Naylor PH; Oates KK; Coss MC; Erdos MR; Naylor CW; Goldstein AL
    Int J Immunopharmacol; 1992 Oct; 14(7):1267-78. PubMed ID: 1452411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma.
    Pica F; Fraschetti M; Matteucci C; Tuthill C; Rasi G
    Anticancer Res; 1998; 18(5A):3571-8. PubMed ID: 9858941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, controlled study of thymosin-alpha1 therapy in patients with anti-HBe, HBV-DNA-positive chronic hepatitis B.
    Zavaglia C; Severini R; Tinelli C; Franzone JS; Airoldi A; Tempini S; Bettale G; Ideo G
    Dig Dis Sci; 2000 Apr; 45(4):690-6. PubMed ID: 10759236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thymosin-alpha 1, but not interferon-alpha, specifically inhibits anchorage-independent growth of hepatitis B viral transfected HepG2 cells.
    Moshier JA; Mutchnick MG; Dosescu J; Holtz TK; Akkary S; Mahakala K; Merline JR; Naylor PH
    J Hepatol; 1996 Dec; 25(6):814-20. PubMed ID: 9007707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immune and inflammation confusion in severe sepsis and effects of bi-immunomodulation therapy: a prospective, randomized, controlled clinical trial].
    Zhou LX; Tan JJ; Li YN; Luo HT; Shao YH; Qiang XH; Yu TO; Ma MY; Mao KJ; Fang B
    Zhonghua Yi Xue Za Zhi; 2009 Apr; 89(15):1028-33. PubMed ID: 19595251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of thymosin alpha 1 on cellular immune function in elderly patients with malignant tumor].
    Yang YM; Lu XY; Huang WD; Shen MY
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2003 Aug; 32(4):339-41. PubMed ID: 12970939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thymosin in the early diagnosis and treatment of high risk homosexuals and hemophiliacs with AIDS-like immune dysfunction.
    Naylor PH; Schulof RS; Sztein MB; Spira TJ; McCurdy PR; Darr F; Kessler CM; Simon GL; Goldstein AL
    Ann N Y Acad Sci; 1984; 437():88-99. PubMed ID: 6398657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thymalfasin (thymosin-alpha 1) therapy in patients with chronic hepatitis B.
    Liaw YF
    J Gastroenterol Hepatol; 2004 Dec; 19(12):S73-5. PubMed ID: 15641208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thymosin alpha(1) application augments immune response and down-regulates tumor weight and organ colonization in BALB/c-mice.
    Beuth J; Schierholz JM; Mayer G
    Cancer Lett; 2000 Oct; 159(1):9-13. PubMed ID: 10974400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biodistribution of synthetic thymosin alpha1 in the serum, urine and major organs of mice.
    Badamchian M; Mora CA; Baumann CA; Paino JE; Goldstein AL
    Int J Immunopharmacol; 1997 Feb; 19(2):59-66. PubMed ID: 9278175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.